Table 6 lists the assessment data for Lipohypertrophy, Lipoatrophy or Both. Looking at the figures excluding the 10 individuals who were on insulin marked ‘not relevant’, [where we are uncertain what ‘not relevant’ means (-it should mean not on insulin)], there was a reported 13.8% Lipohypertrophy, 1.8% Lipoatrophy and of these, 1.5% with both.

Table 6 Assessment

Excluding Not Relevant Insulin Rx ** 2005 n = 1405

Category
n
%
% (Exc
Missing)
Total
%
% (Exc
Missing)
Total
Lipohypertrophy *
88
13.0%
14.3%
677
12.8%
15.1%
687
Lipoatrophy *
22
3.3%
3.6%
670
3.2%
3.8%
680
Both Lipohypertrophy
and Lipoatrophy*
20
3.0%
3.0%
677
2.9%
3.4%
680
Table 6 Assessment continued...

Excluding Not Relevant Insulin Rx ** 2010 n = 2131

Category
n
%
% (Exc
Missing)
Total
%
% (Exc
Missing)
Total
Lipohypertrophy *
208
13.8%
13.9%
1497
13.8%
15.5%
1506
Lipoatrophy *
27
1.8%
1.8%
1496
1.8%
2.1%
1504
Both Lipohypertrophy
and Lipoatrophy*
23
1.5%
1.5%
1497
1.5%
1.7%
1507

*only patients on insulin
** includes 10 marked not relevant in 2005 and includes 9 marked not relevant in 2010